Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

August 11, 2017: By Jon Swedien

ImprimisImprimis Pharmaceuticals’ gross revenues related to ophthalmology totaled $4.7 million in Q2-2017, a 70 percent increase over Q2-2016, the San Diego-based company reported Aug. 10.

The company’s total revenues for Q2-2017 were $6.9 million, a 40 percent increase compared with Q2-2016, said Imprimis, a pharmaceutical company focused on increasing patient access and affordability to critical medicines.

Imprimis had a net income of $1.5 million, or $0.07 per share of common stock (basic). CEO Mark Baum said it was the company’s first quarter of recorded net income.

The company also noted that it achieved the milestone of its products being used in 1 million patient eyes since the launch of its ophthalmic portfolio in April 2014.

And Imprimis announced that it created a new wholly owned subsidiary, Surface Pharmaceuticals, Inc., which will focus on ocular surface disease treatments that are expected to be developed as branded drugs through the FDA’s 505(b)(2) development pathway.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

Alcon to Launch Clareon IOL at ESCRS Meeting

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

Valeant Launches $1 Billion Private Senior Notes Offering

STAAR Surgical Appoints Scott Barnes, MD, as New CMO

Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

Maryland Team Wins First Phase of NEI Contest to Create Human Retina

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022